| HOME >> MEDICINE >> TECHNOLOGY |
3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues 23
3.4.3 Non Pharmacological Therapy Recommended for UI and BPH 23
4 Global Urological Disorders Market: Therapeutic Landscape 24
4.1 Benign Prostatic Hyperplasia Market 24
4.1.1 Introduction 24
4.1.2 Sales Value 24
4.1.3 Annual Cost of Therapy 26
4.1.4 Treatment Usage Patterns 27
4.1.5 Market Share by Geography 32
4.1.6 Generics' Share of the Global BPH Market 35
4.2 Urinary Incontinence (UI) Market 36
4.2.1 Introduction 36
4.2.2 Sales Value 37
4.2.3 Annual Cost of Therapy 39
4.2.4 Treatment Usage Patterns 40
4.2.5 Market Share by Geography 45
4.2.6 Generics' Share in the Global UI Market 49
4.3 Urinary Tract Infections Market 51
4.3.1 Introduction 51
4.3.2 Sales Value 51
4.3.3 Annual Cost of Therapy 53
4.3.4 Treatment Usage Patterns 54
4.3.5 Market Share by Geography 59
4.3.6 Generics' Share of the Global UTI Market 62
5 Global Urological Disorders Market: Geographical Landscape 64
5.1 Geographical Break-up 64
5.2 The US 67
5.2.1 Sales Value 67
5.2.2 Annual Cost of Therapy 68
5.2.3 Treatment Usage Patterns 69
5.3 Top Five Countries in Europe 75
5.3.1 Sales Value 75
5.3.2 Annual Cost of Therapy 76
5.3.3 Treatment Usage Patterns 77
5.4 Japan 83
5.4.1 Sales Value 83
5.4.2 Annual Cost of Therapy 84
5.4.3 Treatment Usage Patterns 85
6 Global Urological Disorders Market: Pipeline Analysis 90
6.1 Introduction 90
6.1.1 Research and Development Pipeline – UI 91
6.1.2 Research and Development Pipeline – BPH 93
6.1.3 Research and Development Pipeline – UTI 95
6.2 Profiles of Key Late-Stage Drugs in the Urological Diso
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |